The MUK five protocol: a phase II randomised, controlled, parallel group, multi-centre trial of carfilzomib, cyclophosphamide and dexamethasone (CCD) vs. cyclophosphamide, bortezomib (Velcade) and dexamethasone (CVD) for first relapse and primary refractory multiple myeloma-Reference-Cited by-同舟云学术

The MUK five protocol: a phase II randomised, controlled, parallel group, multi-centre trial of carfilzomib, cyclophosphamide and dexamethasone (CCD) vs. cyclophosphamide, bortezomib (Velcade) and dexamethasone (CVD) for first relapse and primary refractory multiple myeloma

Published:2016-05-17 Issue:1 Volume:16 Page:
ISSN:2052-1839
Container-title:BMC Hematology
language:en
Short-container-title:BMC Hematol

Author:

Brown Sarah, ,Hinsley Samantha,Ballesteros Mónica,Bourne Sue,McGarry Paul,Sherratt Debbie,Flanagan Louise,Gregory Walter,Cavenagh Jamie,Owen Roger,Williams Cathy,Kaiser Martin,Low Eric,Yong Kwee

Publisher

Springer Science and Business Media LLC

Subject

Hematology,Molecular Biology

Link

http://link.springer.com/content/pdf/10.1186/s12878-016-0053-9.pdf

Reference19 articles.

1. Bertaso AG, Wong DT, Liew GY, Cunnington MS, Richardson JD, Thomson VS, et al. Aortic annulus dimension assessment by computed tomography for transcatheter aortic valve implantation: differences between systole and diastole. Int J Cardiovasc Imaging. 2012;28(8):2091–8. doi: 10.1007/s10554-012-0018-4 .

2. Dimopoulos MA, San-Miguel JF, Anderson KC. Emerging therapies for the treatment of relapsed or refractory multiple myeloma. Eur J Haematol. 2011;86(1):1–15. doi: 10.1111/j.1600-0609.2010.01542.x .

3. Kropff M, Bisping G, Schuck E, Liebisch P, Lang N, Hentrich M, et al. Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma. Br J Haematol. 2007;138(3):330–7. doi: 10.1111/j.1365-2141.2007.06656.x .

4. Fu W, Delasalle K, Wang J, Song S, Hou J, Alexanian R, et al. Bortezomib-cyclophosphamide-dexamethasone for relapsing multiple myeloma. Am J Clin Oncol. 2012;35(6):562–5. doi: 10.1097/COC.0b013e31822043f6 .

5. Reece DE, Rodriguez GP, Chen C, Trudel S, Kukreti V, Mikhael J, et al. Phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myeloma. J Clin Oncol. 2008;26(29):4777–83. doi: 10.1200/JCO.2007.14.2372 .

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ixazomib with cyclophosphamide and dexamethasone in relapsed or refractory myeloma: MUKeight phase II randomised controlled trial results;Blood Cancer Journal;2022-04-01

2. Carfilzomib or bortezomib in combination with cyclophosphamide and dexamethasone followed by carfilzomib maintenance for patients with multiple myeloma after one prior therapy: results from a multicenter, phase II, randomized, controlled trial (MUKfive);Haematologica;2021-04-29

3. The role of carfilzomib in treatment of newly diagnosed multiple myeloma;Future Oncology;2018-12

4. The power of proteasome inhibition in multiple myeloma;Expert Review of Proteomics;2018-11-14

5. Evaluation of thrombosis-related biomarkers before and after therapy in patients with multiple myeloma;Journal of Blood Medicine;2018-01